Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Trump's proposal to restrain drug prices is expected to be modest. Photo: Alex Wong/Getty Images
There are two really big things to watch in President Trump's speech today about drug prices: how much of this plan can be enacted without Congress' help, and the extent to which it takes aim at the actual prices of prescription drugs, rather than trying to rearrange the way the system divvies up those costs.
What we're hearing: There's always room for a surprise with this administration, but so far, all signs point toward a relatively modest proposal.
- The latest I've heard about the contents of the proposal is about the same as what we were hearing before this speech was delayed last week: Some sort of regulatory nod to value-based pricing is seen as a strong possibility, as is some language on trade.
- Health and Human Services secretary Alex Azar and FDA commissioner Scott Gottlieb — both of whom are more steeped in conservative health policy than Trump — have already laid out an agenda that focuses heavily on promoting more competition from generic drugs and targets various middlemen, including hospitals and pharmacy benefit managers.
What they're saying: The White House's proposal will likely fall largely along those same lines.
- Senior administration officials provided very few details in a call with reporters last night, though they did promise "the most comprehensive plan" from "any president."
- They said the plan would address drugs' list prices (though that appears to be largely through increased competition); crack down on other countries' low payment rates (which is hard to do); and reduce out-of-pocket spending.
Threat level: Many of the most muscular and controversial policies in Trump's speech will probably be reiterations of what was in his budget proposal — meaning they would require congressional action, meaning drug companies and hospitals have a better chance of fighting to a draw.
The speech is scheduled for 2 p.m.